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involvement were classified as nonresponders with respect
to proteinuria reduction. Which of these patients had stabiliza-
tion of kidney function versus progression is not clearly
delineated.
Although DNAJB9 levels were previously found to be ele-
vated in patients with FGN [7] and there was hope it might
have a role as a noninvasive disease marker [6], serum levels in
this pilot study did not change with treatment or correlate with
response. While the potential pathogenic role and ability to
serve as a diagnostic biomarker need further evaluation (espe-
cially given the inverse correlation with eGFR that was previ-
ously mentioned), there unfortunately is no evidence to support
a prognostic role based on currently available data.
With this study, Erickson et al. [1] have taken on the
challenging task of determining a therapeutic strategy for an ex-
ceptionally rare glomerular disease with a complex pathophysi-
ology and a poor prognosis. While DNAJB9’s role as a
noninvasive serum marker for FGN is likely a fumble (at least
at this point in time), the authors show forward progress in de-
fining a role for rituximab in the treatment of this disease.
Given single-center studies for rare diseases are limited by sam-
ple size and large-scale randomized trials are often cost and
time prohibitive, future efforts should focus on multicenter, in-
ternational collaborations. This will not only help address con-
founding variables that become problematic in small studies,
but will also allow for subgroup analysis to identify subsets of
patients most likely to benefit from a particular treatment.
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The regulation of potassium homoeostasis changes dramatically
in patients with kidney failure who are treated by
haemodialysis. With the kidney largely out of the equation, hae-
modialysis patients rely on potassium removal during each
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dialysis session to prevent hyperkalaemia. In addition, the gut
becomes an important accessory organ for potassium excretion
[1]. Despite these adaptations, hyperkalaemia (defined as serum
potassium >5.5 mmol/L) remains a common electrolyte disor-
der occurring in approximately 14% of haemodialysis patients
[2]. Although seemingly counterintuitive, a minority of haemo-
dialysis patients is hypokalaemic (serum potassium
<3.5 mmol/L), and this is usually related to poor dietary intake
[3]. The target serum potassium in haemodialysis is unknown,
but one study suggests that a serum potassium between 4.6 and
5.3 mmol/L is associated with the greatest survival [3]. Of note,
in patients with chronic kidney disease (CKD), this optimal se-
rum potassium range seems to be lower (4.0–4.5 mmol/L) [4].
Furthermore , when analysing serum potassium in haemodialy-
sis patients, it is important to factor in when it was measured
(after the long or short interdialytic interval, time of day and
seasonality), and to analyse serial measurements to exclude
transient hyperkalemia [2, 5]. Nephrologists can manage potas-
sium balance in haemodialysis patients in three ways, including
(i) by modifying the dialysate potassium concentration, (ii) by
prescribing potassium binders and (iii) by modifying dietary
potassium intake (Figure 1). The reason to implement such
interventions is usually driven by recurring predialysis hyperka-
laemia and the related risk of cardiac arrhythmia [6]. Although
the prevention of acute complications is important, another rel-
evant question is how these interventions affect long-term out-
comes in haemodialysis patients. Unfortunately, there is a
scarcity of randomized controlled trials in this area. Therefore,
instead, we need to rely on registries, which often provide useful
insights into how real-world management influences long-term
outcomes. A good example of such a registry is the French
Renal Epidemiology and Information Network (REIN). In this
issue, Mercadal et al. [7] use this registry to analyse the effect of
prescription patterns of dialysate potassium and potassium
binders on survival in over 25 000 patients who started haemo-
dialysis in 2010–13 and were followed until the end of 2014.
Using Cox proportional hazard models, the investigators show
that dialysis centres that used two or three dialysate potassium
concentrations had a lower mortality risk than centres that only
used one formula. In addition, patients who used the potassium
binder sodium or calcium polystyrene sulphonate in a dose of
4–8 or 8 g/day had a lower mortality risk than patients who
did not use potassium binders. Conversely, patients who used
potassium binders in a dose <4 g/day had a higher mortality
risk. Oral potassium supplements, which were used in 6% of
patients, were not associated with a survival benefit. What does
this study teach us on potassium management in haemodialysis
patients and what are the implications for clinical practice?
D I A L Y S A T E P O T A S S I U M
An unresolved issue is whether predialysis hyperkalaemia or a
high dialysate–serum potassium gradient is the most important
risk factor for adverse outcomes in haemodialysis patients
(Figure 1) [5, 8]. The most commonly used dialysate potassium
concentration varies widely per country with some countries
using predominantly 1–2 mmol/L and other countries using
3–4 mmol/L [9]. Pun and Middleton [10] reviewed the nine ret-
rospective studies that analysed the association between the di-
alysate potassium concentration and outcome, which usually
was sudden cardiac death or all-cause mortality. Although five
studies identified an increased risk of adverse outcomes with
lower dialysate potassium (defined as <2 or <3 mmol/L), two
studies found no association, and two studies found associa-
tions that favoured lower dialysate potassium [10]. Using sales
data, Mercadal et al. [7] show that over time a lower dialysate
potassium concentration was being used less frequently. For ex-
ample, the percentage of centres using <2 mmol/L decreased
from 57% to 49%, whereas the use of 3 mmol/L or 4 mmol/L
increased from 89% to 91% and from 3% to 13%, respectively.
This trend seems to echo the recent literature in which most
studies linked a low dialysate potassium to an increased risk of
adverse outcomes [10]. However, this was not a universal find-
ing, because Mercadal et al. [7] also showed that the occasional
use of dialysate potassium <2 mmol/L was associated with
lower mortality compared with no use. This heterogeneity
seems to suggest that it is impossible to select one ideal dialysate
potassium concentration, and that the dialysate potassium pre-
scription needs to be personalized, as proposed by others previ-
ously [11]. The data by Mercadal et al. [7] confirm this
impression, because centres that used more dialysate potassium
concentrations had lower mortality rates. A limitation of the
study by Mercadal et al. was that serum potassium measure-
ments were not included, and that therefore analysis of the dial-
ysate–serum potassium gradient was not possible. That aside,
Mercadal et al. and others have called to change the practice of
‘the regrettable routine use of a single dialysate potassium con-
centration’ [3, 7]. Equally regrettable is the fact that the evidence
for a positive effect of a more personalized approach has not yet
reached clinical practice. Redaelli et al. [12] performed a ran-
domized cross-over trial to compare a fixed dialysate potassium
concentration with a strategy during which the dialysate potas-
sium concentration was adjusted to obtain a constant dialysate–
serum potassium gradient. The latter approach reduced the
arrhythmogenic effect of a fixed dialysate potassium concentra-
tion. It is important to emphasize that not only low dialysate
potassium but also low calcium and magnesium contribute to
this arrhythmogenic effect [10, 13]. In addition to the arrhyth-
mogenic effect, a lower dialysate potassium concentration may
also affect blood pressure during and after dialysis (Figure 1).
Gabutti et al. [14] showed that the risk of intra-dialysis hypo-
tension was inversely correlated to the potassium concentration
in the dialysate. Conversely, dialysate potassium concentrations
of 1 and 2 mmol/L produce ‘rebound hypertension’ 1 h after di-
alysis, a phenomenon that was not observed with a dialysate po-
tassium concentration of 3 mmol/L [15]. In summary, the
inclination to lower the dialysate potassium concentration in
haemodialysis patients with recurring hyperkalaemia may in it-
self be harmful by imposing a higher dialysate–serum potas-
sium gradient. In this era of artificial intelligence, it must be
feasible to design more individualized dialysate potassium pre-
scriptions that receive feedback from serial measurements of se-
rum potassium. Indeed, mathematical modelling of potassium
profiling has been proposed [16] and may benefit from
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emerging technologies using in-line monitoring of potassium
with optical ion-selective microsensors [17]. Because less potas-
sium is removed with a more constant dialysate–serum potas-
sium gradient, this also implies that potassium management in
haemodialysis patients should not solely rely on the dialysate
potassium concentration.
P O T A S S I U M B I N D E R S
Potassium binders reduce serum potassium because they ex-
change potassium for sodium or calcium in the gastrointestinal
tract and thereby limit potassium absorption (Figure 1). In the
study by Mercadal et al. [7], 37% of patients used potassium
binders at the start of the observation period, although this de-
creased over time. Another French registry study observed a
much higher potassium binder prescription rate of 61% [2]. Of
note, prescription may differ from actual use, as some potas-
sium binders are poorly palatable thereby reducing adherence.
In both French registries, patients were usually prescribed the
potassium binder sodium polystyrene sulphonate [2, 7]. In a
small randomized clinical trial in patients with CKD, sodium
polystyrene sulphonate was superior to placebo and lowered se-
rum potassium by approximately 1 mmol/L [18]. A concern re-
garding the use of sodium polystyrene sulphonate, however, is
that it can cause colonic necrosis as a rare side-effect [19]. The
gastrointestinal side-effects of sodium polystyrene sulphonate
were recently studied more systematically in a population-
based study from Canada and a CKD-based study from Sweden
that also included patients treated with haemodialysis [20, 21].
Both studies showed that the use of sodium polystyrene sulpho-
nate was associated with a higher risk of gastrointestinal com-
plications, including intestinal ischaemia or thrombosis,
ulceration or perforation, and resection or ostomy [20, 21].
Although the incidence rate for these serious complications was
still low, both studies provided a clear signal for caution [20,
21]. In the previous 5 years, two novel potassium binders have
been introduced in nephrology and cardiology, including
patiromer and sodium zirconium cyclosilicate. Both potassium
binders have recently also been studied in haemodialysis
patients. A retrospective cohort study showed that patiromer ef-
fectively reduced serum potassium in haemodialysis patients,
with an average decrease in serum potassium of 0.5 mmol/L
[22]. In a randomized, double-blind and placebo-controlled
clinical trial, sodium zirconium cyclosilicate reduced the inci-
dence of predialysis hyperkalaemia [23]. More specifically, 41%
of patients had a predialysis serum potassium of 4.0–5.0 mmol/
L during at least three of four haemodialysis treatments after
the long interdialytic interval [23]. Although the use of
patiromer and sodium zirconium cyclosilicate appears to be
safe in clinical trial settings, post-marketing surveillance should
monitor for gastrointestinal side-effects. Another consideration
for all potassium binders is that they will increase absorption of
the electrolyte for which potassium is exchanged (sodium or
calcium), which could potentially contribute to sodium over-
load or vascular calcification [24]. Thus, both the older and
newer potassium binders may help to manage hyperkalaemia in
haemodialysis patients, but the question is how this affects
long-term outcomes. A paradoxical finding in the study by
Mercadal et al. [7] was that prescription of higher doses of po-
tassium binders was associated with lower mortality, whereas
lower dosing was associated with higher mortality. The authors
acknowledge that these associations are likely explained by fac-
tors other than potassium control. An important alternative ex-




























FIGURE 1: Schematic of potassium balance during haemodialysis and how it may affect mortality. The three possibilities for intervention—
dietary potassium content, potassium binders and dialysate potassium—are shown in pink font. See text for further details.
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potassium binders more often consume a potassium-rich diet,
which in itself is associated with better survival [25]. Another
interesting observation by another study was that patiromer re-
duced blood pressure in patients with CKD, hyperkalaemia and
the use of renin–angiotensin system inhibitors [26]. Although
this study requires confirmation, an antihypertensive effect of
potassium binders might be explained by lowering of plasma al-
dosterone [26]. If this is a dose-dependent class effect of potas-
sium binders, this could also add to the explanation of why
higher doses of potassium binders associate with lower mortal-
ity (Figure 1).
D I E T A R Y P O T A S S I U M I N T A K E
Rather than binding potassium after dietary intake, a more di-
rect strategy against hyperkalaemia could be to prescribe a low
potassium diet (Figure 1). In patients with a tendency to de-
velop hyperkalaemia, a dietary potassium intake of <3 g/day
(<77 mmol/day) is recommended [27]. Of note, the general
population and patients with CKD already consume a relatively
low potassium diet [25, 28, 29]. A recent systematic review and
meta-analysis compared the effects of lower and higher dietary
potassium intake in patients with CKD (including patients
treated with dialysis) on serum potassium and mortality [30].
This review found that a potassium-restricted diet (1295 mg/
day) lowered serum potassium by 0.22 mmol/L compared with
an unrestricted—but still low potassium—diet (1570 mg/day).
Furthermore, a low potassium diet (1670 mg/day) was associ-
ated with a 40% reduction in mortality hazard compared with
higher dietary potassium intake (4414 mg/day). However, the
evidence to support these effects was classified as very low-
quality evidence [30]. A small randomized controlled trial ana-
lysed the effect of dietary potassium restriction for 2 years on
nerve function in patients with CKD Stage G3 or G4 [31]. The
intervention caused modest but significant reductions in dietary
potassium intake (3272 versus 3874 g/day) and serum potas-
sium (4.6 versus 4.8 mmol/L), which was sufficient to improve
the total neuropathy score (the primary outcome). This study
illustrates that dietary potassium restriction may have benefits
beyond lowering serum potassium, although the study had sev-
eral limitations [31]. At the same time, emerging evidence indi-
cates that higher dietary potassium intake may be beneficial,
even for patients with CKD [28]. To date, 11 cohort studies ana-
lysed the association between urinary potassium excretion (as a
proxy for dietary intake) and kidney outcomes in patients with
CKD [32]. Although the majority of these studies showed that a
higher urinary potassium excretion was associated with a lower
risk of adverse kidney outcomes or mortality, this was not a
consistent finding. To address the possibility of a causal link be-
tween dietary potassium depletion and kidney outcomes, we
are currently conducting a randomized, double-blind and
placebo-controlled trial with potassium supplementation in
patients with CKD [29]. Higher dietary potassium intake has
been shown to reduce blood pressure and the risk of stroke in
subjects without CKD and prevents kidney damage in experi-
mental models of CKD [28]. Because a high potassium diet usu-
ally consists of fruits and vegetables, potassium-independent
factors such as low animal protein, high-fiber content and an
alkaline diet may also play a role. Indeed, a randomized clinical
trial showed that both alkali treatment and fruits and vegetables
can reduce kidney injury in patients with CKD [33]. To take ad-
vantage of these effects, the need for clinical trials comparing a
potassium-restricted diet with the combination of a potassium-
liberalized diet and potassium binders in patients treated with
haemodialysis has recently been emphasized [34].
T O T A L B O D Y P O T A S S I U M
This editorial so far has focused on the effects of potassium
interventions on the predialysis serum potassium concentration
and the dialysate–serum potassium gradient. However, potas-
sium is primarily an intracellular cation, where it plays a crucial
role in cellular function. Therefore, it is also important to con-
sider how interventions change intracellular potassium concen-
tration and total body potassium, and how this relates to
outcomes (Figure 1). Measurement of intracellular electrolyte
concentrations and whole-body counting of naturally radioac-
tive potassium can be used to provide insight into the ‘black
box’ of the intracellular compartment. Unexpectedly, such
measurements reveal that patients with CKD or patients on
haemodialysis often have a total body potassium deficit, despite
their tendency to develop hyperkalaemia (Figure 2) [35, 36].
For example, the intracellular potassium concentration and the
resting membrane potential were lower in muscle cells of
patients with CKD compared with healthy subjects [37]. The
initiation of haemodialysis normalized intracellular potassium,
but did not improve the resting membrane potential. Similarly,
total body potassium is up to 10% lower in haemodialysis
patients compared with control subjects [35, 36] (Figure 2).
When patients transit from predialysis care to haemodialysis,
total body potassium was restored in some patients, whereas in
others it decreased [38]. Preliminary data suggest that total
body potassium depletion is also associated with increased mor-
tality (Figure 1) [35]. Because more than 60% of potassium re-
moval derives from the intracellular compartment [10], dialysis
may contribute to reducing total body potassium. In this regard,
the combination of a low potassium diet and a low dialysate po-
tassium concentration may exhaust intracellular potassium
stores. Of note, hyperkalaemia and total body potassium defi-
ciency may co-exist if factors prevent the entry of potassium
into cells. Such factors are not uncommon in haemodialysis
patients and include metabolic acidosis, insulin resistance and
the use of beta-blockers (Figure 1). Of interest, a high dialysate
sodium also contributes to the interdialytic increase in serum
potassium because hypertonicity causes a shift of potassium out
of cells [39]. Conversely, one could postulate that a higher dialy-
sate potassium may improve sodium removal during haemo-
dialysis and contributes to better blood pressure control. To this
end, we are currently conducting a cross-over study to compare
the effects of a dialysate potassium of 4.0 mmol/L with
2.0 mmol/L on blood pressure, volume and intracellular sodium
and potassium.
In conclusion, to improve potassium management and po-
tentially long-term outcomes in haemodialysis, we believe it is
important to integrate all factors that determine potassium bal-
ance and apply a personalized approach that is dynamic and
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relies on more frequent serum potassium measurements and
ideally also on total body potassium.
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FIGURE 2: Comparison of total body potassium (TBK, ratio of mea-
sured versus expected normal) between haemodialysis patients and
controls (patients with essential hypertension). Data are based on
Williams et al. [36]. Measured TBK in controls and haemodialysis
patients were 3390 and 2810 mmol, respectively. Time on dialysis
varied from <1 to >5 years. TBK was measured before dialysis.
Values are mean 6 standard error.
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